One dose of brachytherapy might be enough for prostate patients: study

From a patient’s perspective, who wouldn’t want a single-treatment prostate cancer regimen that worked as well as more involved alternatives? A clinical trial of high-dose-rate (HDR) brachytherapy has found that one dose can be a safe and effective solution. The study was done at Oakland University’s William Beaumont School of Medicine, Royal Oak, Mich., and is available online in the International Journal of Radiation Oncology Biology Physics, the flagship journal of the American Society of Radiation Oncology.